These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 6203890)

  • 1. Investigations into the mechanism of action of the antibacterial agent norfloxacin.
    Crumplin GC; Kenwright M; Hirst T
    J Antimicrob Chemother; 1984 May; 13 Suppl B():9-23. PubMed ID: 6203890
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of ciprofloxacin, norfloxacin and nalidixic acid.
    Bauernfeind A; Petermüller C
    Eur J Clin Microbiol; 1983 Apr; 2(2):111-5. PubMed ID: 6222896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of appearance of resistant variants to norfloxacin and nalidixic acid.
    Duckworth GJ; Williams JD
    J Antimicrob Chemother; 1984 May; 13 Suppl B():33-8. PubMed ID: 6234273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bactericidal activity of norfloxacin and nine other urinary tract antibiotics against Gram-negative bacilli causing bacteriuria in chronically catheterized patients.
    Tenney JH; Warren JW
    J Antimicrob Chemother; 1983 Mar; 11(3):287-90. PubMed ID: 6221010
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in-vitro activity of norfloxacin and selected antimicrobial agents against urinary tract pathogens and Neisseria gonorrhoeae.
    Sweet RL; Ohm-Smith MJ; Hadley WK
    J Antimicrob Chemother; 1982 Dec; 10(6):553-7. PubMed ID: 6219085
    [No Abstract]   [Full Text] [Related]  

  • 6. Comparative in vitro activity of norfloxacin and four other chemotherapeutics against urinary gram-negative isolates.
    Esposito S; Galante D; Pennucci C; Barba D; Limauro D; Scioli C
    Chemioterapia; 1984 Jun; 3(3):196-9. PubMed ID: 6241506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the in vitro activity of norfloxacin and other drugs on amoxicillin-resistant uropathogenic isolates.
    Piccolomini R; Allocati N; Catamo G
    Chemioterapia; 1984 Jun; 3(3):167-72. PubMed ID: 6241505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Norfloxacin (MK-0366, AM-715): in vitro activity and cross-resistance with other organic acids including quality control limits for disk diffusion testing.
    Jones RN; Barry AL
    Diagn Microbiol Infect Dis; 1983 Jun; 1(2):165-72. PubMed ID: 6232084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The antimicrobial spectrum of norfloxacin.
    Newsom SW
    J Antimicrob Chemother; 1984 May; 13 Suppl B():25-31. PubMed ID: 6234272
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bactericidal effects of norfloxacin towards bacteria in urine.
    Lacey RW; Lord VL; Howson GL
    J Antimicrob Chemother; 1984 May; 13 Suppl B():49-54. PubMed ID: 6234275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bactericidal effect against Escherichia coli of nalidixic acid and four structurally related compounds.
    Stevens PJ
    J Antimicrob Chemother; 1980 Jul; 6(4):535-42. PubMed ID: 6159344
    [No Abstract]   [Full Text] [Related]  

  • 12. Incomplete cross-resistance of nalidixic and pipemidic acid-resistant variants of Serratia marcescens against ciprofloxacin, enoxacin, and norfloxacin.
    Traub WH
    Chemotherapy; 1985; 31(1):34-9. PubMed ID: 3156026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates.
    Khan MY; Gruninger RP; Nelson SM; Klicker RE
    Antimicrob Agents Chemother; 1982 May; 21(5):848-51. PubMed ID: 6213200
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of MK-0366 against clinical urinary pathogens including gentamicin-resistant Pseudomonas aeruginosa.
    Downs J; Andriole VT; Ryan JL
    Antimicrob Agents Chemother; 1982 Apr; 21(4):670-2. PubMed ID: 6211142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The assessment of antimicrobial activity in an in-vitro model of the treatment of bacterial cystitis.
    Greenwood D
    J Antimicrob Chemother; 1984 May; 13 Suppl B():43-8. PubMed ID: 6234274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Norfloxacin--a new antibacterial agent with anti-pseudomonal activity.
    Peddie BA
    N Z Med J; 1982 Oct; 95(717):712. PubMed ID: 6216426
    [No Abstract]   [Full Text] [Related]  

  • 17. Effect of nalidixic acid on recombination and DNA repair of Escherichia coli K-12 strains.
    Inan S; Kalaycioglu A
    Indian J Exp Biol; 1996 Oct; 34(10):949-53. PubMed ID: 9055644
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Laboratory evaluation of enoxacin: comparison with norfloxacin and nalidixic acid.
    Teoh-Chan CH; Cowlishaw A; Eley A; Slater G; Greenwood D
    J Antimicrob Chemother; 1985 Jan; 15(1):45-52. PubMed ID: 3156113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro studies with ciprofloxacin, a new 4-quinolone compound.
    Reeves DS; Bywater MJ; Holt HA; White LO
    J Antimicrob Chemother; 1984 Apr; 13(4):333-46. PubMed ID: 6233250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protein- and RNA-synthesis independent bactericidal activity of ciprofloxacin that involves the A subunit of DNA gyrase.
    Lewin CS; Howard BM; Smith JT
    J Med Microbiol; 1991 Jan; 34(1):19-22. PubMed ID: 1703579
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.